Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Ensitrelvir and Oral Contraceptives
NCT06775730Phase 1Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Dec 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ensitrelvir in coronavirus disease 2019 (COVID-19), sponsored by Shionogi & Co., Ltd. Primary endpoints: Maximum Plasma Concentration of Ethinyl Estradiol at Day 24, Maximum Plasma Concentration of Drospirenone at Day 24 and 4 more. Started Dec 2024; status: completed.
02
Drugs
ensitrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06775730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06775730.